

Appl. No. : 10/828,795
Filed : April 21, 2004

REMARKS

Applicants have amended the claims to more specifically claim the combination of naltrexone and bupropion, along with the methods of use thereof. Applicants have canceled Claims 1-7, 12-18, and 20-21 and have added new Claim 22-37. Claims 8-10 and 19 are amended. By these amendments, Applicants make no admission as to the patentability of the canceled subject matter. Applicants reserve the right to pursue the canceled subject matter in this or any other patent application, including a continuation, continuation-in-part, or divisional application claiming priority to the instant application.

Support for the amendments is found throughout the specification, particularly at:

For amendments to Claims 9, 10, and 19: Paragraphs [0021], [0031], [0039], [0225], and [0226];

For new Claims 22, 23, 26, 27, 30, and 31: Paragraphs [0046], [0052], and [0055];

For new Claims 24, 28, and 32: Paragraph [0043];

For new Claim 33: Paragraph [0078].

Applicants respectfully submit that the amended claims are patentable as set forth herein, particularly in view of the results set forth in Example 8 of the specification.


Applicants have enclosed a check in the amount of \$200 in connection with this Amendment. If this is incorrect, please charge any additional required fees, or credit any over payments, to Deposit Account No. 11-1410.

Applicants invite the Examiner to contact the undersigned if any issues can be resolved through a telephone conversation.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Feb. 17, 2006

By: 
Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550